Search

Your search keyword '"Ba-Ssalamah, A"' showing total 129 results

Search Constraints

Start Over You searched for: Author "Ba-Ssalamah, A" Remove constraint Author: "Ba-Ssalamah, A" Topic contrast media Remove constraint Topic: contrast media
129 results on '"Ba-Ssalamah, A"'

Search Results

1. Acute adverse reactions after multiple initially well-tolerated gadolinium-based contrast-enhanced abdomen MRIs in pediatric patients.

2. Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture.

3. Contrast-enhanced ultrasound of the liver: Vascular pathologies and interventions.

4. Contrast-enhanced ultrasound of the liver: basics and interpretation of common focal lesions.

5. Are dilution, slow injection and care bolus technique the causal solution to mitigating arterial-phase artifacts on gadoxetic acid-enhanced MRI? A large-cohort study.

6. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?

7. Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging.

8. Respiratory motion artifacts during arterial phase imaging with gadoxetic acid: Can the injection protocol minimize this drawback?

9. Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications.

10. Assessment of Orthotopic Liver Transplant Graft Survival on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters.

11. Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial.

12. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

13. The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach.

14. Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging.

15. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study.

16. Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography.

17. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases.

18. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation.

19. Is there a role for dynamic swallowing MRI in the assessment of gastroesophageal reflux disease and oesophageal motility disorders?

20. Gadobenate dimeglumine-enhanced 3.0-T MR imaging versus multiphasic 64-detector row CT: prospective evaluation in patients suspected of having pancreatic cancer.

21. MR imaging of benign focal liver lesions.

22. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

23. The optimal use of contrast agents at high field MRI.

24. Contrast-enhanced, high-resolution, susceptibility-weighted magnetic resonance imaging of the brain: dose-dependent optimization at 3 tesla and 1.5 tesla in healthy volunteers.

25. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.

26. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].

27. [Use of contrast agent in high-field MRI (3 T)].

28. MR contrast agent at high-field MRI (3 Tesla).

29. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases.

30. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.

31. Magnetic resonance imaging contrast enhancement of brain tumors at 3 tesla versus 1.5 tesla.

32. Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP.

33. Diagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study

34. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging

35. Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course.

36. Inter- and intra-reader agreement for gadoxetic acid–enhanced MRI parameter readings in patients with chronic liver diseases

37. Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging

38. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging

39. Quantification of liver function using gadoxetic acid-enhanced MRI

40. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid–enhanced MRI Predict Outcomes in Chronic Liver Disease?

41. Influence of dilution on arterial-phase artifacts and signal intensity on gadoxetic acid–enhanced liver MRI.

42. Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD

43. Imaging of inflammatory disease of the pancreas

45. Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging

46. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases

47. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging

48. Assessment of Orthotopic Liver Transplant Graft Survival on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters

49. Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial

50. The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis—a multiparametric approach

Catalog

Books, media, physical & digital resources